Extrait

To determine the efficacy (as assessed by progression free survival (PFS) ) of vandetanib when compared to placebo in patients with differentiated thyroid cancer that is either locally advanced or metastatic who are refractory or unsuitable for radioiodine therapy.

Critère d'inclusion

• Papillary Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Cancer,Advanced Thyroid cancer

Liens

• ictrp
• euctr
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• euctr